Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial-Reference-Cited by-同舟云学术

Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial

Published:2021-03 Issue:2 Volume:6 Page:e134
ISSN:2444-8664
Container-title:Porto Biomedical Journal
language:en
Short-container-title:

Author:

Tavares Margarida,Farraia Mariana,Silva Susana,Ribeiro Ana Margarida,Severo Milton,Paciência Inês,Ribeiro Raquel,Hespanhol Venceslau,Guimarães João Tiago,Almeida Jorge,Magro Fernando,Sarmento António,Oliveira Ana Marta,Moreira André

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Biochemistry, Genetics and Molecular Biology

Reference20 articles.

1. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan;Chan;Emerg Microbes Infect.,2020

2. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell.,2020

3. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding;Lu;Lancet.,2020

4. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury;Kuba;Nat Med.,2005

5. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury;Liu;Sci China Life Sci.,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients;Inflammation Research;2023-01-08

2. Role of monteleukast in the treatment of covid – 19 an overview;Journal of Pharmacovigilance and Drug Research;2022-09-01